Sandoz Group AG

What does Sandoz Group own?
Sandoz Group owns the Sandoz brand for generic medicines and biosimilars. The company markets approximately 1,300 generic medicines worldwide and has a pipeline of more than 400. Key biosimilar products include Pyzchiva, Binocrit, Hyrimoz, Omnitrope, Wyost and Jubbonti, Afqlir, and Tyruko. The company also operates manufacturing facilities and distribution centers globally.

Is Sandoz Group publicly traded?
Yes, Sandoz Group AG is publicly traded on the SIX Swiss Exchange under ticker SDZ. The company began trading independently in October 2023 following its spinoff from Novartis.

Who founded Sandoz Group?
Sandoz Group was established in 2003 as the generics division of Novartis. The company became independent through a spinoff from Novartis in October 2023. The Sandoz name traces its heritage back to 1886, when the original Sandoz chemical company was founded in Basel, Switzerland.

Where is Sandoz Group headquartered?
Sandoz Group is headquartered in Basel, Switzerland. The company relocated its corporate headquarters from Risch to Basel in April 2025. The registered office is at Centralbahnstrasse 4, 4051 Basel.

How many brands does Sandoz Group own?
Sandoz Group owns one main brand: Sandoz, for generic medicines and biosimilars. The brand includes approximately 1,300 generic medicines and a growing portfolio of biosimilars.

Who owns Sandoz Group?
Sandoz Group is a publicly traded company with a dispersed shareholder base. Institutional investors hold the majority of shares, with no single controlling shareholder. Novartis does not retain a significant stake following the spinoff. Gilbert Ghostine serves as Chairman of the Board of Directors.

What is Sandoz Group's revenue?
Sandoz Group reported FY2025 net sales of USD 11.1 billion, up 5 percent at constant currencies and 7 percent in USD. Core EBITDA was USD 2.4 billion with a margin of 21.7 percent. The company's 2026 guidance projects mid to high single-digit net sales growth at constant currencies.

Who is the CEO of Sandoz Group?
Richard Saynor serves as Chief Executive Officer of Sandoz Group AG. Remco Steenbergen serves as Chief Financial Officer. Gilbert Ghostine serves as Chairman of the Board of Directors.

The Sandoz name traces its heritage back to 1886, when the original Sandoz chemical company was founded in Basel, Switzerland. In 1996, Ciba-Geigy and Sandoz AG merged to form Novartis. In 2003, Novartis consolidated its generics operations under the Sandoz division name, honoring the heritage of the original company. This created a focused generics business within the Novartis group.

The Sandoz division grew through acquisitions and organic growth in the 2000s and 2010s. Notable acquisitions included Eon Labs in 2005, Sabex in 2006, and Fougera in 2012. These acquisitions expanded Sandoz's portfolio and geographic reach. The company became one of the world's largest generic pharmaceutical companies and pioneered the development of biosimilars, launching the world's first biosimilar in 2006.

In 2018, Novartis announced plans to explore strategic options for Sandoz, including a potential spinoff. The generics division faced pressure from investors to unlock value. In August 2022, Novartis announced that it would spin off Sandoz as an independent publicly traded company. The spinoff was completed in October 2023, with Sandoz beginning trading on the SIX Swiss Exchange under ticker SDZ. Novartis did not retain a significant stake.

Following the spinoff, Sandoz established its own board of directors and management team. Gilbert Ghostine was elected Chairman of the Board of Directors, and Richard Saynor was appointed Chief Executive Officer. The company focused on operational efficiency, cost management, and biosimilar development. In April 2025, Sandoz relocated its headquarters from Risch to Basel, Switzerland.

In 2025, Sandoz achieved significant milestones. The biosimilar share of total net sales increased to 30 percent, three years ahead of schedule. Key launches included Wyost and Jubbonti in the US and Europe, Pyzchiva in Europe, Afqlir (aflibercept) in Europe, and Tyruko (natalizumab) in the US. The company also announced a strategic partnership to create a European biosimilar platform and expanded through business development, including the acquisition of Cimerli-related assets.

In 2026, Sandoz will celebrate three milestones: 20 years of pioneering biosimilars, 80 years of antibiotics manufacturing, and 140 years of heritage rooted in Switzerland.

Sandoz has set science-based targets aligned with the Paris Agreement and submitted them to the Science Based Targets initiative (SBTi) for validation. The company is committed to achieving net-zero emissions by 2050, with interim goals set for 2030 and 2035. Sandoz is also targeting zero water quality impact and zero waste to landfill by 2030.

In 2025, Sandoz reduced carbon emissions by 5 percent at intensity level, with 2 percent absolute reduction. Three Sandoz labs were awarded My Green Lab certification, with the goal of certifying 100 percent of Sandoz labs by 2027. The company achieved 96 percent Code of Ethics training completion and 95 percent Anti-Bribery training completion.

Sandoz maintains an inclusive culture with over 50 percent female representation in both its global workforce and executive management team. The company achieved removal of historical salary requests for 100 percent of new employee offers and earned a collective company rating of 4 from Glassdoor, above the global pharmaceutical industry benchmark of 3.5. ESG-linked executive compensation reflects the company's dedication to fairness, dignity, and sustainability.